l ■ l IIII Immuno-oncology Autoimmune diseases In Vivo Leader: First to Demonstrate Systemic CRISPR Gene Editing in Humans 12 * Lead development and commercial party; ** Rights to certain in vivo targets; *** Milestones & royalties only AATD: alpha-1 antitrypsin deficiency; CAR-T: chimeric Antigen Receptor T Cells; HSC: hematopoietic stem cells; OSC: ocular stem cells; TCR: T cell receptor Capable of delivering to multiple tissue types for various therapeutic applications | --- | --- | --- | --- | |-------| ...